More tools:Markets·Screener·Research·Chat

Cel-Sci Corporation (CVM) Financial Statements

Cel-Sci Corporation
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG001SBRBG1
XASE · usd
1.58▼ 0.07 (-4.55%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales—
EV / Revenue—
EV / EBITDA
Financial Highlights
Revenue (TTM)—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close1.65
Day's Range1.64 – 1.77
52-Week Range0.89 – 11.40
Volume275.6K
Avg Volume186.6K
Share Statistics
Shares Outstanding
Employees44
ExchangeXASE
Listed1983-12-08
Share count as of August 10, 2026
Loading Income Statement…
Key questions about Cel-Sci Corporation (CVM)
What is Cel-Sci Corporation's Market Cap?
Cel-Sci Corporation's Market Cap is $27.7M, based on as-reported figures from SEC (XBRL) filings.
What is Cel-Sci Corporation's Enterprise Value?
Cel-Sci Corporation's Enterprise Value is $31.6M, based on as-reported figures from SEC (XBRL) filings.
What is Cel-Sci Corporation's EV / EBITDA?
Cel-Sci Corporation's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Cel-Sci Corporation's Net Income (TTM)?
Cel-Sci Corporation's Net Income (TTM) is -$22.7M, based on as-reported figures from SEC (XBRL) filings.
What is Cel-Sci Corporation's EBITDA?
Cel-Sci Corporation's EBITDA is -$18.5M, based on as-reported figures from SEC (XBRL) filings.
What is Cel-Sci Corporation's Diluted EPS (TTM)?
Cel-Sci Corporation's Diluted EPS (TTM) is -1.29, based on as-reported figures from SEC (XBRL) filings.
What is Cel-Sci Corporation's Net Debt?
Cel-Sci Corporation's Net Debt is $3.9M, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Research and Development Expense
Selling, General and Administrative Expense
Total operating expenses
Operating loss
Net Interest Income
Non-Operating Income (Expense)
Net loss
Net loss available to common shareholders
Earnings Per Share (Diluted)